CA2465807A1 - Use of bisindolmaleimide and gemcitabine for the treatment of cancer - Google Patents

Use of bisindolmaleimide and gemcitabine for the treatment of cancer Download PDF

Info

Publication number
CA2465807A1
CA2465807A1 CA002465807A CA2465807A CA2465807A1 CA 2465807 A1 CA2465807 A1 CA 2465807A1 CA 002465807 A CA002465807 A CA 002465807A CA 2465807 A CA2465807 A CA 2465807A CA 2465807 A1 CA2465807 A1 CA 2465807A1
Authority
CA
Canada
Prior art keywords
days
compound
formula
gemcitabine
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465807A
Other languages
English (en)
French (fr)
Inventor
Kapil Dhingra
Lars Holger Breimer
Urvashi Hooda Dhingra
Steve Ritland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2465807A1 publication Critical patent/CA2465807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002465807A 2001-11-20 2002-11-11 Use of bisindolmaleimide and gemcitabine for the treatment of cancer Abandoned CA2465807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33397701P 2001-11-20 2001-11-20
US60/333,977 2001-11-20
PCT/EP2002/012572 WO2003043632A2 (en) 2001-11-20 2002-11-11 Use of bisindolmaleimide and gemcitabine for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2465807A1 true CA2465807A1 (en) 2003-05-30

Family

ID=23305029

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465807A Abandoned CA2465807A1 (en) 2001-11-20 2002-11-11 Use of bisindolmaleimide and gemcitabine for the treatment of cancer

Country Status (8)

Country Link
US (1) US20030139373A1 (https=)
EP (1) EP1448189A2 (https=)
JP (1) JP2005509663A (https=)
CN (1) CN1589143A (https=)
AR (1) AR037543A1 (https=)
AU (1) AU2002366195A1 (https=)
CA (1) CA2465807A1 (https=)
WO (1) WO2003043632A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
MX388093B (es) 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
ES2203111T3 (es) * 1998-03-17 2004-04-01 F. Hoffmann-La Roche Ag Maleimidas bisindol sustituidas para la inhibicion de proloferacion celular.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6548531B2 (en) * 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy

Also Published As

Publication number Publication date
AR037543A1 (es) 2004-11-17
US20030139373A1 (en) 2003-07-24
WO2003043632A3 (en) 2003-12-11
WO2003043632A2 (en) 2003-05-30
AU2002366195A8 (en) 2003-06-10
AU2002366195A1 (en) 2003-06-10
EP1448189A2 (en) 2004-08-25
JP2005509663A (ja) 2005-04-14
CN1589143A (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
RU2587013C2 (ru) Комбинированная химиотерапия
US20120157472A1 (en) Method for treating colorectal cancer
CN105311029A (zh) 抗肿瘤活性的喹啉衍生物
US7799783B2 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
JP2018513130A (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
WO2012080151A1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
US6548531B2 (en) Method for cancer therapy
AU2002246080A1 (en) Method for Cancer Therapy
CA2465807A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP3957310B1 (en) Composition comprising sotagliflozin and a tyrosine kinase activity inhibitor for use in the treatment of cancer
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
RU2284818C2 (ru) Комбинированная химиотерапия
CN111617081B (zh) 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途
CN113274394A (zh) 一种治疗酪氨酸激酶抑制剂耐药的非小细胞肺癌的药物组合物
CA2191230C (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
US20250302813A1 (en) Recombinant methioninase in the treatment of cancer
MX2013004924A (es) Combinacion de bevacizumab y 2,2-dimetil-n((s)-6-oxo-6,7-dihidro-5 h-dibenzo[b,d] azepin-7-il)-n'-(2,2,3,3,3-pentafluoro-propil)-malo namida para el tratamiento de desordenes proliferativos.
CN115381954B (zh) 一种用于治疗骨肉瘤的联合用药物
JPH03170424A (ja) がんの処置
AU735319B2 (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
HK40059774A (en) Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer
WO2005007155A1 (ja) 医薬組成物
JPH03133913A (ja) 新規美白剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued